Seres reports Q3 2022 net loss $60M; SER-109 BLA accepted for Priority Review with PDUFA April 26, 2023

Seres Therapeutics, Inc.

2022-Q3 EPS reported -$1.77 revenue$6,153,000

Net loss of $60.0M in Q3 2022 vs net income of $68.2M in Q3 2021; R&D expenses $43.1M.
FDA accepted SER-109 BLA for Priority Review; PDUFA target action date April 26, 2023.
ECOSPOR IV open-label study: 91.3% of patients achieved sustained clinical response at 8 weeks.
Cash, cash equivalents and marketable securities $233.0M as of Sept 30, 2022.
SER-155 cohort 1 enrollment complete; DSMB safety review by year end; initial data early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Seres Therapeutics, Inc. reported financial results for third quarter 2022.

Period: third quarter 2022
Result: reported results

Exact text from the filing

Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 and provided operational updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-275406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.